This study aims to evaluate the efficacy and safety of intrapleural JMKX000197 compared with intrapleural cisplatin in patients with malignant pleural effusion.
Participants with advanced solid tumors diagnosed by histopathology or cytopathology.
Moderate to large pleural effusions require intervention.
ECOG performance status: 0 to 2.
Life expectancy ≥ 3 months
Bilateral pleural effusion or concurrent peritoneal effusion, or concurrent pericardial effusion.
Pleural effusion is either encapsulated or severely separated; Or merge with chylothorax; Or combined with infectious pleural effusion.
Known allergies to the study drug or its excipient components.
Have participated in other clinical trials within 28 days prior to randomization.